StockpollyBeta
Get App
Delisting riskPopularity #4,715
MSLE · NASDAQ · Biotechnology

Satellos Bioscience (MSLE)

Developing SAT-3247, an oral muscle-repair therapy for Duchenne muscular dystrophy.

$8.87
After hours−0.13 (−1.44%)
At close$9.00(−1.96%)

In millions of USD, except per-share figures

In millionsQ4 FY20Dec 2020Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue—0000000000—
Gross profit000000000000
16875566681012
Research & development146533544579
032221222223
General & administrative000021222223
Other expenses000000000000
Operating income−1−6−8−7−5−5−6−6−6−8−10−12
0011—1010000
Interest income—10000000001
Interest expense000000000000
Other non-operating income00000−1000000
Income before tax−1−7−7−6—−3−6−6−6−7−10−11
Income tax expense000000000000
Net income from continuing operations0−7−7−6—−3−6−6−6−7−10−11
Net income0−7−7−6—−3−6−6−6−7−10−11
EPS, basic−$5.69−$0.69−$0.73−$0.64−$0.98−$0.45−$0.44−$0.36−$0.36−$0.48−$0.53−$0.55
EPS, diluted−$5.69−$0.69−$0.73−$0.64−$0.98−$0.45−$0.44−$0.36−$0.36−$0.48−$0.53−$0.55
Weighted average shares, basic0999914141414151821
Weighted average shares, diluted0999914141414151821
EBITDA−1−6−8−7—−3−6−6−6−8−10−12
Depreciation & amortization—000—000000—
EBIT−1−6−8−7−5−3−6−6−6−8−10−12